The Breakthrough Therapy designation for VAX-24 will grant Vaxcyte access to the FDA’s Fast Track program.
Vaxcytehas been granted Breakthrough Therapy designation by the FDA for VAX-24, an investigational 24-valent pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease in adults, according to a news release.1 The FDA’s decision came after positive topline results from the Phase 1/2 proof-of-concept study that tested the safety, tolerability, and immunogenicity of VAX-23 in adults aged 18 to 64 years.
The vaccine met primary safety and tolerability objectives with a safety profile similar to that of PCV20 (Prevnar 20). The company intends to move forward into a Phase 3 program after the study demonstrated VAX-24 meeting or exceeding established regulatory immunogenicity standards for all 24 serotypes at the 2.2 mcg dose.
Vaxcyte will have access to all elements of the FDA’s Fast Track program for the further development of VAX-24 and will receive guidance and support from the FDA.
“We are pleased to have received this important designation for VAX-24, which we believe underscores the public health need for broader protection from IPD, as well as the importance of innovative technology platforms in vaccine development, such as our cell-free, carrier-sparing approach,” said Jim Wassil, executive vice president and chief operating officer of Vaxcyte.
Topline safety, tolerability, and immunogenicity data from a pivotal phase 3 noninferiority study are expected in 2025.
References
1. Vaxcyte’s VAX-24 granted FDA Breakthrough Therapy Designation for the prevention of invasive pneumococcal disease in adults. News Release. Vaxcyte. January 5, 2023. Accessed January 10, 2023.
Socioeconomic Disparities Persisted Alongside Improving Vaccination Rates In US Over 11-Year Period
April 16th 2024Findings indicating that socioeconomic disparities widened gaps in vaccination timeliness signal the need for increased efforts to promote timely vaccination among children from families with lower income and those without private insurance.
Pfizer Announces Positive Top-Line Data for Abrysvo Immunization in Adults Aged 18 to 59 Years
April 9th 2024Abrysvo is currently approved to treat RSV-associated lower respiratory tract disease in adults aged 60 years and older, and in infants through the immunization of pregnant individuals.